Alethia’s pipeline places great emphasis on the development of monoclonal antibodies generated against its disease-specific targets. AB-16B5, an IgG2 monoclonal antibody for the inhibition of cancer-associated epithelial-to-mesenchymal transition (EMT), is currently under study in animal models of invasive cancers and shows positive pre-clinical results in representative models of prostate and beast cancer. AB-3D3 is lytic IgG1 monoclonal antibody  developed against a small cell-surface protein for the treatment of ovarian cancer.


Furthermore, two monoclonal antibody lead candidates are under evaluation as inhibitors of osteoclast differentiation in our severe bone loss programs.

Product pipeline
Cancer-associated EMT
Ovarian cancer
Bone degradationClusterin.htmlOvarian_cancer.htmlBone_loss.htmlshapeimage_1_link_0shapeimage_1_link_1shapeimage_1_link_2shapeimage_1_link_3